Neurocrine Biosciences Announces Publication Of Positive Results From Kinect 3 Phase III Study Of INGREZZA TM (Valbenazine) For The Treatment Of Tardive Dyskinesia Post author:Sam Post published:March 20, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Amicus Releases More Impressive Pompe Disease Data at WORLDSymposium February 7, 2018 Bay Area's GigaGen Moves to New Space to Accommodate Growth January 22, 2018 <b>Victoria Laughman</b> Named Executive Vice President Of Sales For Opko Health's BioReference August 17, 2017
<b>Victoria Laughman</b> Named Executive Vice President Of Sales For Opko Health's BioReference August 17, 2017